Healthcare >> CEO Interviews >> October 21, 2016
Adi Mohanty became Co-Chief Executive Officer of BioTime, Inc. in October 2015. He is also a Director of BioTime company OncoCyte Corporation and BioTime affiliate Asterias Biotherapeutics. Mr. Mohanty was formerly with Shire plc, a specialty pharmaceutical company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014; as Senior Vice President, Business and Technical Operations, from 2012 to 2013; and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as VP at Transkaryotic Therapies from 2002 to 2005, when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty received an MBA from Saint Mary’s College, and has an M.S. and B.S. in chemical engineering. Profile
Mr. Mohanty: BioTime is the leading regenerative medicine company in the
